Koch-WeserJ.SidelV. W.SweetR. H.KanarekP.EatonA. E.: Factors Determining Physician Reporting of Adverse Drug Reactions. Comparison of 2000 Spontaneous Reports with Surveillance Studies at the Massachusetts General Hospital. New Eng. J. Med.280: 20–26, 1969.
2.
Koch-WeserJ.: Disease Drugs Cause. New Eng. J. Med.279: 1286–1287, 1968.
3.
Koch-WeserJ.: Definition and Classification of Adverse Drug Reactions. Drug Information Bull.2: 72–78, 1968.
4.
Koch-WeserJ.SellersE. M.: Drug Interactions with Coumarin Anticoagulants. New Eng. J. Med.285:487–498, 547–558, 1971.
5.
AvellanedaM.: Interferencia de los Barbituricos en la Accion del Tromexan. Medicina (B. Aires)15: 109–115, 1955.
6.
DaytonP. G.TarcanY.ChenkinT.WeinerM.: The Influence of Barbiturates on Coumarin Plasma Levels and Prothrombin Response. J. Clin. Invest.40: 1797–1802, 1961.
7.
CucinellS. A.ConneyA. H.SansurM.BurnsJ. J.: Drug Interactions in Man. I. Lowering Effect of Phenobarbital on Plasma Levels of Bishydroxycoumarin (Dicumarol) and Diphenylhydantoin (Dilantin). Clin. Pharmacol. Ther.6: 420–429, 1965.
8.
RobinsonD. S.MacDonaldM. G.: The Effect of Phenobarbital Administration on the Control of Coagulation Achieved during Warfarin Therapy in Man. J. Pharmacol. Exp. Ther.153: 250–253, 1966.
9.
SiggA.PestalozziH.GaussA.KollerF.: Verstarkung der Antikoagulantienwirkung durch Butazolidin. Schweiz. Med. Wschr.86: 1194–1195, 1956.
10.
AggelerP. M.O'ReillyR. A.LeongL.KowitzP. E.: Potentiation of Anticoagulant Effect of Warfarin by Phenylbutazone. New Eng. J. Med.276: 496–501, 1967.
11.
JickH.MiettinenO. S.ShapiroS.LewisG. P.SiskindV.SloneD.: Comprehensive Drug Surveillance. J. A. M. A.213: 1455–1460, 1970.
12.
Koch-WeserJ.: Quinidine-induced Hypoprothrombinemic Hemorrhage in Patients on Chronic Warfarin Therapy. Ann. Intern. Med.68: 511–517, 1968.
13.
Koch-WeserJ.: Potentiation by Glucagon of the Hypoprothrombinemic Action of Warfarin. Ann. Intern. Med.72: 331–335, 1970.
14.
SellersE. M.Koch-WeserJ.: Potentiation of Warfarin-induced Hypoprothrombinemia by Chloral Hydrate. New Eng. J. Med.283: 827–831, 1970.
15.
Boston Collaborative Drug Surveillance Program: Interaction between Chloral Hydrate and Warfarin. New Eng. J. Med.286: 53–55, 1972.
16.
SellersE. M.Koch-WeserJ.: Kinetics and Clinical Importance of Displacement of Warfarin from Albumin by Acidic Drugs. Ann. N. Y. Acad. Sci.179: 213–225, 1971.
17.
SloneD.JickH.LewisG. P.ShapiroS.MiettinenO.S.: Intravenously Given Ethacrynic Acid and Gastrointestinal Bleeding. A Finding Resulting From Comprehensive Drug Surveillance. J. A. M. A.209: 1668–1671, 1969.
18.
Koch-WeserJ.SidelV. W.FedermanE. B.KanarekP.FinerD. C.EatonA. E.: Adverse Effects of Sodium Colistimethate. Manifestations and Specific Reaction Rates during 317 Courses of Therapy. Ann. Intern. Med.72: 857–868, 1970.
19.
Boston Collaborative Drug Surveillance Program: Excess of Ampicillin Rashes Associated with Allopurinol or Hyperuricemia. New Eng. J. Med., in press.
20.
SellersE. M.Koch-WeserJ.: Displacement of Warfarin from Human Albumin by Dioxide and Ethacrynic, Mefenamic and Nalidixic Acids. Clin. Pharmacol. Ther.11: 524–532, 1970.
21.
VesellE. S.PassanatiG. T.GreeneF. E.: Impairment of Drug Metabolism in man by Allopurinol and Nortriptyline. New Eng. J. Med.283: 1484–1488, 1970.
22.
RobinsonD. S.BenjaminD. M.McCormackJ. J.: Interaction of Warfarin and Nonsystemic Gastrointestinal Drugs. Clin. Pharmacol. Ther.12: 491495, 1971.
23.
VesellE. S.PassanantiG. T.LeeC. H.: Impairment of Drug Metabolism by Disulfiram in Man. Clin. Pharmacol. Ther.12: 785–792, 1971.
24.
SellersE. M.LangM.Koch-WeserJ.: Potentiation by Trichloroethylphosphate of Warfarin-induced Hypoprothrombinemia. Clin. Pharmacol. Ther.13: 152, 1972.
25.
SellersE. M.LangM.Koch-WeserJ.LeBlancE.KalantH.: Interaction of Chloral Hydrate and Ethanol in Man. I. Metabolism. Clin. Pharmacol. Ther.13: 3749, 1972.
26.
SellersE. M.CarrG.BernsteinJ. G.SellersS.Koch-WeserJ.: Interaction of Chloral Hydrate and Ethanol in Man. II. Hemodynamics and Performance. Clin. Pharmacol. Ther.13: 50–58, 1972.
